India ▾

RPG Life Sciences Limited — Q4 FY25 earnings call

Call held 29 Apr 2025

Management summary

RPG Life Sciences delivered a strong Q4 and full year FY25 performance, marked by robust business and profit growth, significant margin expansion, and a record cash surplus. The company successfully modernized its manufacturing facilities, securing key international approvals. While the API segment faced a temporary slowdown due to a fire incident and overall domestic market growth was impacted by DPCO pricing, the company's strategic focus on volume-driven growth and new product development positions it for continued healthy performance across all segments.

Highlights

  • Q4 FY25 business growth of 12.7%, significantly outpacing market growth.

  • EBITDA margin for Q4 FY25 surged by 380 bps to 21.4%, and for FY25 by 310 bps to 26.4%.

  • Full year FY25 EBITDA, PBT, and PAT all grew approximately 27%.

  • Achieved a record cash surplus of INR 266 crores, including INR 163.7 crores from operations.

  • API plant is approved by TGA and PMDA, and the Ankleshwar formulations plant is approvable from EU, following INR 140 crores investment in modernization.

Concerns

  • API segment growth for FY25 was 6%, with a slowdown in H2 due to a fire incident impacting one block of the plant.

  • Debtor days increased to 48 days from around 30 days due to the increasing component of International Formulations and API business, which have higher receivables norms.

  • Domestic market growth was slightly less than the previous year, primarily due to negligible DPCO price increases (0.0055%) on 35% of the business and some pricing pressure in certain quality products.

Key financials

2 periods

Q4 FY25

  • Revenue Growth
    —
    YoY +12.7%
  • EBITDA Growth
    —
    YoY +37%
  • PBT Growth
    —
    YoY +41%
  • PAT Growth
    —
    YoY +40%
  • EBITDA Margin
    21.4%
  • PBT Margin
    17.5%
  • PAT Margin
    12.9%

FY25

  • Revenue Growth
    —
    YoY +12%
  • EBITDA Growth
    —
    YoY +27%
  • PBT Growth
    —
    YoY +27%
  • PAT Growth
    —
    YoY +27%
  • EBITDA Margin
    26.4%
  • PBT Margin
    23%
  • PAT Margin
    17.1%
  • Cash Surplus (Operations)
    ₹163.7 Cr
  • Cash Surplus (Total)
    ₹266 Cr

What they filed

Q1 FY27: revenue up 16.0%, net profit up 19.2% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue172 173 143 169 182 +6%180 +4%177 +24%196 +16%
EBITDA46 49 25 35 39 −15%40 −18%33 +32%44 +26%
Net profit4 35 117 26 37 +825%22 −37%30 −74%31 +19%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

SegmentContributionGrowth
Domestic Formulations66%10%
International Formulations20%24%
API14%6%

Capital allocation

high confidence
  • Capex Capex disclosed
    • Modernizing API plant at Navi Mumbai and Formulations plant at Ankleshwar ₹140 Cr
    Now with the two plants, we have an API plant at Navi Mumbai and Formulations plant at Ankleshwar. These two plants being ready or modernized, as I mentioned earlier with investment INR 140 crores.
  • Liquidity Cash ₹266 Cr Cumulative cash surplus from operations was INR 163.7 crores, increasing to INR 266 crores including exceptional items (land monetization).
    Cash surplus, which we have been accumulating over the years, also recorded a record level. INR 163.7 crores is a cumulative surplus which we got from operations and around INR 266 crores if we include the exceptional items, which happened during the last year.

Guidance & targets

Profitability

  • Tax Rate Profitability · going ahead · High confidence 25% to 26%
    Yes. So going ahead we should be in the range of between 25% to 26%.

    — Mr. Vishal Shah

Product Pipeline

  • New API Molecules Product Pipeline · end FY26 and FY27 · Medium confidence around 12
    And we have close to about 12 new molecules being developed by the R&D now. They should see the light of the day by end FY '26 and FY '27.

    — Mr. Yugal Sikri

  • New International Formulations Product Pipeline · end FY26 or FY27 · Medium confidence around 12 to 13
    And we are also developing, as I mentioned earlier, around 12 to 13 new formulations, new formulation. I mentioned earlier that those will see the light of the day by the end of fourth quarter FY '26 or FY '27 onwards.

    — Mr. Yugal Sikri

R&D

  • R&D Spend as % of Sales R&D · ongoing · High confidence ~2% to 3%
    In terms of the R&D spend as a percentage of sales, we should be close to about 2% or so, should be in the range of 2% to 3% to my mind.

    — Mr. Yugal Sikri

  • R&D Spend as % of Sales (Future) R&D · as more molecules are developed · Low confidence a couple of percentage points more
    It might move up a couple of percentage points as we develop more molecules. Currently, we are developing, I said, around 20 molecules, 20 products in both the businesses put together. As we expand from 20 to 40, it might move up a couple of percentage more.

    — Mr. Yugal Sikri

Domestic Market

  • Volume Growth Domestic Market · next year · Medium confidence around 7% to 8%
    So if I assume these numbers and take this assumption, so next year, is it safe to assume that around mid-teens kind of volume, mid-teens kind of value growth will be there in the domestic market?

    — Mr. Yugal Sikri

  • Price Increase Domestic Market · next year · Medium confidence low single digit
    We expect it could be low single digit, very low single digit, but we expect some kind of price increase the government should give.

    — Mr. Yugal Sikri

  • Value Growth Domestic Market · next year · Medium confidence mid-teens
    So if I assume these numbers and take this assumption, so next year, is it safe to assume that around mid-teens kind of volume, mid-teens kind of value growth will be there in the domestic market?

    — Mr. Yugal Sikri

Receivables

  • International Business Receivables Receivables · going forward · High confidence increase
    And to answer your question straight, yes, you should expect some increase in the account receivables going forward.

    — Mr. Yugal Sikri

What to watch in Q1 FY26

API Plant Restoration & Normalization

H2 FY26 (September/October 2025)
Current One block impacted by fire, expected to normalize from H2 FY26
Target Plant fully restored and API business growth normalizing

Why it matters

Ensuring full operational capacity and recovery of the API segment is crucial for overall business growth and margin stability.

Let me assure you that we have set up three work streams to make sure that we get back the plant as good as the new plant, which we had earlier by September end or October.

Risks & concerns

  • DPCO (Drug Price Control Order) Impact on Pricing

    medium

    DPCO products, which constitute 35% of the business, received negligible price increases (0.0055%) in FY25, impacting overall price growth. Management expects low single-digit price increases from the government in the future.

    Management acknowledged

  • Fire Incident at API Plant

    medium

    An unfortunate fire incident impacted one block of the API plant, causing a 1-quarter impact on the API business in Q4 FY25 and an estimated INR 8-10 crores in lost sales. Restoration is expected by September/October, with adequate insurance coverage.

    Management acknowledged

  • Pricing Pressure in Specific Product Categories

    low

    Some quality products in the domestic business faced pricing pressure, although the immunosuppressant portfolio (mature molecules) did not. The company mitigates this through customer-customized marketing and relationship building.

    Management acknowledged

Q&A highlights

6 direct
Chronic vs. Institutional Sales Mix Direct
The CVM, which I talked about, does not include the institution and the MABs. This is the pure chronic. I actually mentioned that it is excluding Nephro and Onco. It does not include Nephro and Onco. ... Institutional business is not that very significant.

Clarifies the definition of 'pure chronic' business and confirms institutional sales are not a significant contributor, reinforcing focus on branded business.

Asked by Sudarshan Padmanabhan

Inventory and Receivables Management Direct
Yes, it's the change of the product mix. We have a strong control on inventories. Inventory levels have actually come down. The receivables, which you see a little increase is, our domestic business continues to be under control, absolutely no problem. In case we are expanding the International Formulations business, you would have seen International Formulations business has grown by 24%. And generally, the receivables in the international business are a little higher, which is the norm of that business.

Explains the slight increase in receivables as a normal consequence of the growing International Formulations business, while confirming strong inventory control.

Asked by Sudarshan Padmanabhan

MR Productivity and Margin Expansion Partial
I'm happy to share with you that year-on-year for the last 6 years, we have improvement in productivity. Now as I mentioned, I made that mention in my opening remarks, it has moved up from INR 5.8 lakhs to INR 6.3 lakhs. ... Regarding the margin, yes, as we improve our chronic business, it should add to the margin. But you also know that there are cost pressures also. And there are also the sword of the DPCO hanging on your head, which you can't predict.

Highlights sustained improvement in sales force productivity but acknowledges external pressures like DPCO and rising costs that could impact future margin expansion.

Asked by Sudarshan Padmanabhan

Tax Rate Outlook Direct
Yes. So going ahead we should be in the range of between 25% to 26%.

Provides clear guidance on the expected effective tax rate for the coming years, aiding financial modeling.

Asked by Sudarshan Padmanabhan

API Unit ZLD (Zero Liquid Discharge) Status Direct
Yes. I think the new plant, Mr. Kapoor, is absolutely from the EHS perspective, quite compliant. We had an ETP, which was underground. We have brought it up the ground now, which is functioning. All the compliance measures are very well taken care of. And the ZLD part, which you talked about, also has been put in place. So it's become a state-of-art plant now.

Confirms the successful implementation of ZLD and other EHS compliance measures at the API plant, addressing environmental concerns and ensuring modern operational standards.

Asked by Sajal Kapoor

Domestic Formulation Growth Drivers (Volume, Price, New Launches) Direct
So first, the breakup of domestic formulation in the volume, price and new introduction. the price is around we have around 2.3%. New introduction is 1.1% and rest is volume, which is around 7.3% or so. That's the breakup of three. You'll be happy to know that our growth continues to be driven by volumes, which I think is a good indication of demand generation, which is, I think, a solid part of the DF business.

Provides a detailed breakdown of domestic formulation growth, emphasizing that volume growth is the primary driver, indicating strong demand generation.

Asked by Aditya Chheda

API Business Outlook and Capex Partial
We have close to about 12 new molecules being developed by the R&D now. They should see the light of the day by end FY '26 and FY '27. And that's where we see the API business picking up the trajectory. ... 75% to 80% of our capex has been going in growth, and which is what will continue. So I can't give you any precise answer because it depends upon the product opportunity we get.

Outlines the future growth drivers for the API business through new molecules and confirms that future capex will primarily be growth-oriented, though specific amounts are opportunity-dependent.

Asked by Deepak

API Segment Slowdown in H2 FY25 Direct
Yes. Rashmi, I did mention about the exceptional part. There was an unfortunate incident of fire in our API plant. ... So what you see here in this year is the 1 quarter impact on that API business because it happened which I think going forward from H2 onwards should normalize.

Clarifies that the API segment's H2 slowdown was due to a fire incident, with expectations for normalization from H2 FY26, providing context for the lower annual growth.

Asked by Rashmi Shetty

3 min read 7 chapters

Detailed narrative

Strong Financial Performance in Q4 and Full Year FY25

RPG Life Sciences reported robust financial results for Q4 FY25, with business growth of 12.7% and significant profit growth: EBITDA up 37%, PBT up 41%, and PAT up 40%. This led to substantial margin expansion, with Q4 EBITDA margin surging by 380 basis points to 21.4%. For the full year FY25, business growth was 12%, and EBITDA, PBT, and PAT all grew approximately 27%. Full year EBITDA margin improved by 310 basis points to 26.4%, with PAT margin reaching 17.1%.

Record Cash Surplus and Enhanced Shareholder Value

The company achieved a record cash surplus of INR 266 crores, including INR 163.7 crores generated from operations. This strong cash generation, combined with strategic initiatives, contributed to significant improvements in financial ratios over the past six years. ROCE improved from 9.7% to 32.9%, ROE from 6.7% to 24.3%, and EPS grew from INR 6.5 to INR 66.5, demonstrating substantial value creation for investors.

Segmental Growth and Strategic Focus

In FY25, Domestic Formulations contributed 66% of revenue with 10% growth, outpacing the market. International Formulations grew 24%, contributing 20% to revenue, driven by new products like Sodium Valproate and Sertraline. The API segment contributed 14% with 6% growth. The company's strategy focuses on product portfolio rejuvenation, asset building, customer coverage, sales force productivity, and cost optimization across its three business segments.

Infrastructure Modernization and Regulatory Approvals

RPG Life Sciences invested INR 140 crores in modernizing its API plant in Navi Mumbai and formulations plant in Ankleshwar. The API plant has successfully received approvals from TGA (Australia) and PMDA (Japan), while the Ankleshwar plant is approvable from the EU, with full EU approval expected shortly. These upgrades ensure state-of-the-art facilities and compliance with international standards, supporting future growth.

R&D Pipeline and Future Growth Drivers

The company has established three new R&D setups and is developing around 12 new API molecules and 12-13 new international formulations, expected to be launched by end FY26 and FY27. These new products are anticipated to drive the future trajectory of the API and International Formulations businesses. R&D spend is currently around 2-3% of sales, with potential for a slight increase as more molecules are developed, leveraging a unique R&D process to optimize costs.

Domestic Market Dynamics and Pricing Pressures

Domestic formulation growth in FY25 was primarily volume-driven (7.3%), with price contributing 2.3% and new introductions 1.1%. The overall domestic market growth was slightly lower than the previous year due to negligible price increases (0.0055%) on DPCO-controlled products, which constitute 35% of the business. Management anticipates a low single-digit price increase from the government next year and expects mid-teens value growth in the domestic market, driven by volume and new launches.

API Segment Challenges and Mitigation

The API segment experienced a slowdown in the second half of FY25, with Q4 lost sales estimated at INR 8-10 crores, primarily due to a fire incident impacting one block of the plant. The company has implemented risk mitigation strategies, including engaging third-party manufacturers and CDMOs, and expects the plant to be fully restored by September/October, leading to normalization of API business growth from H2 FY26.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls